VivoPower Analyst Price Targets

Wall Street analyst price targets and consensus rating for VivoPower (VIVO).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingOutperform# Analysts1Avg. Consensus PT$10Upside to Avg. PT+515.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 4, 2026	Noble Capital Markets	Michael Kupinski	Maintained	Outperform	$10
Jul 13, 2026	Noble Capital Markets	Michael Kupinski	Initiate	Outperform	$10

Analyst Ratings News

PRO
Noble Capital Markets Maintains Outperform on VivoPower, Maintains $10 Price Target

Noble Capital Markets analyst Michael Kupinski maintains VivoPower (NASDAQ:VIVO) with a Outperform and maintains $10 price target.

Benzinga Newsdesk

PRO
Noble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

Noble Capital Markets analyst Michael Kupinski initiates coverage on VivoPower (NASDAQ:VIVO) with a Outperform rating and announces Price Target of $10.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Benzinga Insights

PRO
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

HC Wainwright & Co. analyst Yi Chen downgrades Meridian Bioscience (NASDAQ:VIVO) from Buy to Neutral and raises the price target from $30 to $34.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and raises the price target from $28 to $30.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and raises the price target from $27 to $28.

Benzinga Newsdesk

VivoPower PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

VivoPower Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Noble Capital Markets Maintains Outperform on VivoPower, Maintains $10 Price Target

PRO
Noble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

PRO
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

People Also Watch

People Also Watch

VivoPower PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

VivoPower Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONoble Capital Markets Maintains Outperform on VivoPower, Maintains $10 Price Target

PRONoble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

PROHC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

PROHC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

PROHC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

People Also Watch

People Also Watch

PRO
Noble Capital Markets Maintains Outperform on VivoPower, Maintains $10 Price Target

PRO
Noble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

PRO
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28